 30 CR rate at 600 mg in 20 patients with relapsedrefractory NPM1-mutant AML Low frequency of differentiation syndrome, including 5 rate 120 of Grade 3 among NPM1-mutant patients treated at 600 mg 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive Type C meeting with ... The post Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting appeared fi... 